[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pet-ct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pet-ct":203},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,39,65,88,124,152,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100644938","performance-of-amino-acid-pet-in-brain-metastases-100644938",false,"NCT07676448","Performance of Amino Acid PET in Brain Metastases","Static and Dynamic Performance of Amino Acid PET for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)","DYNAMET","Inclusion Criteria:\n\n* Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,\n\nExclusion Criteria:\n\n* Patients who refused the using of their data","ALL","18 Years","90 Years",{"count":21,"type":22},80,"ESTIMATED","OBSERVATIONAL","Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications",[26],"PET-CT","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-30","ACTUAL",{"date":33,"type":22},"2026-08-05",{"date":35,"type":22},"2026-11-03",{"name":37,"class":38},"Central Hospital, Nancy, France","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100612927","pet-ct-in-lymphoma-among-the-eldery-100612927","NCT07259941","PET-CT in Lymphoma Among the Eldery","PET-CT Imaging Findings and Metabolic Parameters in Elderly Patients With Lymphoma","Inclusion Criteria:\n\n\\- Age ≥ 60 years\n\nHistopathological diagnosis of lymphoma\n\nExclusion Criteria:\n\n\\- Presence of other concurrent active malignancies\n\nUncontrolled diabetes mellitus with blood glucose \\> 200 mg\u002FdL at the time of PET\u002FCT scan","60 Years",{"count":48,"type":22},63,"This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET\u002FCT scans.",[26,51,52,53],"Lymphoma","Elderly","Metabolic Parameters",[26,51,52,55],"metabolic parameters","2025-11-21",{"date":58,"type":31},"2025-12-02",{"date":60,"type":22},"2026-01-01",{"date":62,"type":22},"2027-02-01",{"name":64,"class":38},"Assiut University",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100611691","synthetic-pet-from-ct-improves-precision-diagnosis-and-treatment-of-lung-cancer-a-prospective-observational-multicenter-study-100611691","NCT07243873","Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study","Inclusion Criteria:\n\n1. Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;\n2. Voluntarily participate and sign an informed consent form;\n\nExclusion Criteria:\n\n1. History of other malignant tumours;\n2. Image artefacts;\n3. Without pathological diagnostic information;\n4. Without paired CT and FDG-PET scan images.","85 Years",{"count":73,"type":22},10000,"This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.",[76,26],"Lung Cancer","RECRUITING","2025-11-20",{"date":80,"type":31},"2025-11-24",{"date":82,"type":22},"2025-12-01",{"date":84,"type":22},"2026-12-01",{"name":86,"class":38},"Shanghai Pulmonary Hospital, Shanghai, China",5,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100594378","phase-2-18ff-fapi-petct-and-laparoscopy-in-staging-advanced-gastric-cancer-100594378","NCT07018661","[18F]F-FAPI PET\u002FCT and Laparoscopy in Staging Advanced Gastric Cancer","[18F]F-FAPI PET\u002FCT and LAparoscopy in STagIng Advanced Gastric Cancer - a Multicenter Prospective Study","PLASTIC-3","Inclusion Criteria:\n\n* Histologically proven adenocarcinoma of the stomach or the esophagogastric junction (Siewert type III), by gastroscopy;\n* Age greater than or equal to 18 years;\n* Surgically resectable, advanced tumor (cT3-4b, N0-3, M0), as determined on gastroscopy and a contrast-enhanced CT of thorax and abdomen. Intention to perform a gastrectomy, based on a multidisciplinary team meeting and shared decision making;\n* Patients must have given written informed consent;\n* Patients who have recently participated in an interventional study with an investigational medicinal product (IMP) may only participate if an interaction with study procedures is deemed unlikely by the study team (e.g. based on mechanism or washout period).\n\nExclusion Criteria:\n\n* Siewert type I-II esophagogastric junction tumor;\n* Unfit or unwilling to undergo study procedures;\n* Unfit or unwilling to undergo surgery;\n* Pregnancy at time of the \\[18F\\]AlF-FAPI-74 PET\u002FCT scan, due to the investigational PET radiation burden;\n* Incapacitated subjects without decision-making capacity;\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent;\n* Illiterate patients unable to complete the resource use and quality of life questionnaires;\n* Inability to undergo PET\u002FCT scans due to factors such as claustrophobia, weight limits, or the inability to lie flat for the duration of the scan (approximately 30 minutes).",{"count":97,"type":22},250,"INTERVENTIONAL",[100,101],"PHASE2","PHASE3","The goal of this clinical trial is to learn if a new type of scan, FAPI-PET\u002FCT, can help find metastases of gastric cancer. We want to know how well this scan works for this purpose and whether it is less burdensome for patients compared to the methods we currently use to find metastases.\n\nThe main questions it aims to answer are:\n\n* In how many patients can FAPI-PET\u002FCT find metastases, which leads to a change in their treatment plan as decided by their medical team, such as avoiding unnecessary surgeries and changing from treatment meant to cure the disease to treatment focused on comfort (palliative treatment)?\n* In how many patients does FAPI-PET\u002FCT change the diagnostic process as decided by their medical team, like more biopsies or imaging, or changing the type (extent) of surgery needed?\n\nApart from the usual care gastric cancer patients receive, participants will:\n\n* Undergo one additional scan, which will take approximately 2 hours in total (excluding travel time)\n* Complete a number of questionnaires, which will take approximately 4 hours in total",[104,105,106,26],"Locally Advanced Gastric Adenocarcinoma","STOMACH NEOPLASM","Gastric Cancer",[108,109,110,111,112,106,113],"FAPI","18F-FAPI-74","PET\u002FCT","Imaging biomarker","Gastrectomy","Diagnostics","2025-08-20",{"date":116,"type":31},"2025-08-27",{"date":118,"type":31},"2025-07-03",{"date":120,"type":22},"2029-01",{"name":122,"class":38},"Leiden University Medical Center",10,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":98,"phases":134,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100556028","68ga-c1-pet-ct-imaging-in-clear-cell-renal-cell-carcinoma-100556028","NCT06519760","68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Evaluation of Diagnostic Value of 68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Signed written informed consent；\n2. Age ≥18；\n3. Patients with confirmed or suspected clear cell renal cell carcinoma;\n4. Expected survival ≥6 months.\n\nExclusion Criteria:\n\n1. Renal mass is known to be a metastasis of another primary tumor;\n2. Have other malignancies that require treatment;\n3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;\n4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m²;\n5. Pregnant and lactating women or female patients plan to become pregnant within 6 months;\n6. Uncontrolled psychiatric disorders;\n7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).",true,{"count":133,"type":22},200,[135],"NA","The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET\u002FCT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1.\n\nResearchers will compare the diagnostic value of 68Ga-C1 PET\u002FCT and 18F-FDG PET\u002FCT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.",[138,26,139],"Carbonic Anhydrase IX","Clear Cell Renal Cell Carcinoma",[138,141,26,139],"68Ga-C1","2024-11-05",{"date":144,"type":31},"2024-11-07",{"date":146,"type":31},"2024-07-30",{"date":148,"type":22},"2026-12-31",{"name":150,"class":38},"Peking University First Hospital",1,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":163,"conditions":164,"keywords":170,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100426408","image-assisted-optimization-of-proton-radiation-therapy-in-chordomas-and-chondrosarcomas-100426408","NCT04832620","Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas","Defining Optimal Imaging Strategies for Diagnosis, Treatment, and Treatment Evaluation of Chordomas and Chondrosarcomas of the Axial Skeleton","CHIPT","Inclusion Criteria:\n\n* Histologically diagnosed with primary or recurrent chordoma or chondrosarcoma in the axial skeleton (clivus, spine and sacrum)\n* Accepted for standard proton beam therapy\n\nExclusion Criteria:\n\n* Diagnosis other than chordoma or chondrosarcoma is made.\n* Patient refuses (parts) of the standard treatment protocol.\n* Patient refuses MRI due to claustrophobia.\n* Patient not suitable for MRI due to the presence of MRI incompatible implants.\n* Incapacitated patients.\n* Patient doesn't allow coded data to be used for analysis.\n* Patient is under 50 years of age.\n* Lesion size less than 1cm.\n* Patients with WHO 3 and higher.","50 Years",{"count":162,"type":22},40,"Rationale: Chordomas and chondrosarcomas located in the axial skeleton are malignant neoplasms of bone. These tumors share the same clinical challenges, as the effect of the disease is more a function of their local aggressiveness than their tendency to metastasize (20% metastasize). The local aggressive behavior can cause debilitating morbidity and mortality by destruction of nearby located critical neurovascular structures. Imaging has, in addition to histopathology, a role in diagnosis and in guiding (neo)adjuvant and definitive treatment. Despite the low sensitivity to radiotherapy, proton radiotherapy has been successfully used as an adjunct to resection or as definitive treatment for aggressive chordomas and chondrosarcomas, making it a standard indication for proton therapy in the Netherlands.\n\nChordomas and chondrosarcomas consist, especially after previous therapy, of non-viable and viable tumor components. Identification of these viable components by functional imaging is important to determine the effect of previous therapy, as change in total tumor volume occurs more than 200 days after change of functional imaging parameters.\n\nObjective: The main objective of this study is to determine if functional MRI parameters change within 6 months, and earlier than volumetric changes after start of proton beam therapy. This would allow timely differentiation between affected and unaffected (viable) tumor components, which can be used for therapy adjustment.\n\nSecondary objectives: Determine which set of parameters (PET-CT and secondary MRI) can predict clinical outcome (tumor specific mortality, development of metastases, morbidity secondary to tumor activity and morbidity secondary to treatment); determine what type of imaging can accurately identify viable tumor nodules relative to critical anatomical structures; improving understanding of relevance of changing imaging parameters by correlating these with resected tumor.\n\nStudy design: Prospective cohort study Study population: LUMC patients diagnosed with primary or recurrent chordoma or chondrosarcoma in the axial skeleton. A number of 20 new patients per year is expected.\n\nMain study parameters: Volumetric and functional MR imaging parameters including permeability parameters.\n\nSecondary parameters are generated by PET-CT (SUV, MTV and TLG), MR (perfusion, permeability and diffusion), therapy (proton beam dose mapping, surgery) and clinical outcome. End points are disease specific survival, progression free survival (including development of metastases), side effects of treatment, and functional outcome (see CRF). In patients who are treated with surgical resection following neo-adjuvant therapy, the surgical specimen will be correlated with imaging findings.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Treatment and clinical management will not be affected in this study, thus the additional burden, risks, and benefits associated with participation in this study are minimal.\n\nTwo extra MRI and one PET-CT examination will be planned during proton therapy.",[165,166,167,168,26,169],"Bone Neoplasm of Vertebral Column","Chordoma","Chondrosarcoma","Magnetic Resonance Imaging","Proton Therapy",[166,167,171,26,172],"MRI","Proton therapy","2023-11-15",{"date":175,"type":31},"2023-11-18",{"date":177,"type":31},"2021-02-02",{"date":179,"type":22},"2027-12",{"name":122,"class":38},2,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":151},"100359926","fluciclovine-petct-in-multiple-myeloma-patients-100359926","NCT03966443","Fluciclovine PET\u002FCT in Multiple Myeloma Patients","PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose","FLUCIPET","Inclusion Criteria:\n\n* Multiple myeloma patients suitable for ASCT treatment\n\nExclusion Criteria:\n\n* Patients with contraindications to ASCT treatment",{"count":123,"type":22},"Comparison between image findings at aminoacid PET\u002FCT and FDG PET\u002FCT for myeloma patients",[193,26],"Myeloma, Multiple","2019-05-28",{"date":196,"type":31},"2019-05-30",{"date":198,"type":31},"2019-03-01",{"date":200,"type":22},"2029-01-31",{"name":202,"class":38},"Oslo University Hospital","PET CT"]